These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36497135)

  • 41. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Novel Mechanism to Induce BRCAness in Cancer Cells.
    Cai C
    Cancer Res; 2020 Jul; 80(14):2977-2978. PubMed ID: 32669350
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Defining and Modulating 'BRCAness'.
    Byrum AK; Vindigni A; Mosammaparast N
    Trends Cell Biol; 2019 Sep; 29(9):740-751. PubMed ID: 31362850
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
    Pothuri B
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy.
    Ibragimova I; Cairns P
    Methods Mol Biol; 2011; 780():277-91. PubMed ID: 21870267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
    Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
    Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
    Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD
    BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The development of PARP as a successful target for cancer therapy.
    Ferrara R; Simionato F; Ciccarese C; Grego E; Cingarlini S; Iacovelli R; Bria E; Tortora G; Melisi D
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):161-175. PubMed ID: 29260919
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.
    Mekonnen N; Yang H; Shin YK
    Front Oncol; 2022; 12():880643. PubMed ID: 35785170
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
    Abbotts R; Topper MJ; Biondi C; Fontaine D; Goswami R; Stojanovic L; Choi EY; McLaughlin L; Kogan AA; Xia L; Lapidus R; Mahmood J; Baylin SB; Rassool FV
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22609-22618. PubMed ID: 31591209
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update on PARP1 inhibitors in ovarian cancer.
    Sessa C
    Ann Oncol; 2011 Dec; 22 Suppl 8():viii72-viii76. PubMed ID: 22180407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
    Layman RM; Arun B
    Cancer J; 2021 Jan-Feb 01; 27(1):67-75. PubMed ID: 33475295
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
    Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.
    Bortlíková L; Müller P; Vojtěšek B; Rak V; Svoboda M
    Klin Onkol; 2019; 32(Supplementum 3):19-24. PubMed ID: 31627702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.